Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

Setipiprant, a PGD2 inhibitor, and RepliCel, a cell transplantation technology, are being explored as potential hair loss treatments. Current mainstream treatments like Minoxidil and Finasteride have limitations due to side effects and efficacy.

A user with diffuse thinning recommends a root cover-up spray as a temporary, medication-free solution. They plan to consult a dermatologist for treatments like Minoxidil and finasteride while using the spray for special occasions.

A 24-year-old shared their 7-month progress using a topical solution of finasteride 0.1%, minoxidil 5%, and hydrocortisone butyrate 0.08%, along with ketoconazole shampoo, to treat hair loss, reporting no side effects and noticeable hair improvement. They also take vitamin D and biotin supplements, use a dermastamp, and manage Hashimoto's without thyroid medication.

A 25-year-old is using 1mg oral finasteride daily, 2.5mg oral minoxidil daily, and ketoconazole shampoo twice a week for hair loss, with little to no side effects. They experienced initial shedding but have seen positive results and plan to resume microneedling.

The conversation is about finding clascoterone 5% or other effective anti-androgens for hair loss in the UK, with openness to purchasing from outside the UK. A suggestion was made to visit Dublin, where research on the treatment is ongoing.

The conversation discusses a hair loss treatment involving oral minoxidil, topical finasteride, and a custom topical formulation with minoxidil, cetirizine, finasteride, progesterone, and hydrocortisone. The user seeks advice on the effectiveness of these ingredients for diffuse thinning.

The user has been using a treatment of 0.1% topical finasteride, 5% minoxidil, dermastamping, and vitamin D3 supplements for 85 days and is seeing good progress. Other users note the effectiveness of topical finasteride despite it being less potent.

A user experienced significant hair loss after switching from topical to oral finasteride and minoxidil, despite initially seeing great results with the topical treatment. They are seeking advice on whether to return to topical treatments or increase their oral minoxidil dosage.

The user has been using a treatment regimen for hair loss for 8 months, including topical 5% minoxidil, 2.5 mg daily minoxidil, 5 mg finasteride every other day, and vitamins. They shared progress pictures showing little change in the crown area.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

The user is using oral finasteride, topical minoxidil, and tretinoin to treat hair loss. After two months, there is noticeable thickening and maintenance of the hairline.

The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.

The user is excited about starting Clascoterone 5% for hair loss, a DHT blocker, and expects better results when combined with Minoxidil. The prescription costs $199 for 30 ml or $353 for 60 ml, and the user plans to cover the cost by driving for Uber.

The user reported subtle hair regrowth by focusing on scalp health and lifestyle changes, using Nizoral shampoo and methods to reduce inflammation and cortisol, without using finasteride, minoxidil, or other common treatments. Opinions in the conversation varied, with some skeptical of the results and others acknowledging the potential benefits of addressing scalp health and inflammation.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.

PP405 is a new topical drug that reactivates dormant hair follicle stem cells by inhibiting the MPC protein, shifting cell metabolism to glycolysis, and potentially regrowing hair even in bald areas. It differs from minoxidil and finasteride as it does not alter hormones or blood flow but instead targets cell metabolism.

The user has been taking Locklab tablets daily for three months and has experienced scalp itching and small scabbing, with possible hair regrowth. They are seeking feedback on whether others have experienced similar symptoms.

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

The conversation discusses a hair loss treatment regimen involving 2.5mg dutasteride, 10mg oral minoxidil, RU58841, and low-dose testosterone replacement therapy (TRT). The user reports progress without significant side effects, except for facial bloating from minoxidil.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The user is using a regimen of dutasteride, oral and topical minoxidil, Nutrafol, and keto shampoo for hair regrowth, with plans for a hair transplant at the one-year mark. Users suggest adjusting treatments due to scalp inflammation and discuss the potential addition of RU58841, while noting impressive results so far.

The user is experiencing diffuse thinning and excessive sebum production, considering Accutane as a potential solution after trying dutasteride and oral minoxidil without success. Other users suggest treatments like Nizoral shampoo, finasteride, beclomethasone dipropionate lotion, and topical androgen receptor inhibitors.

The conversation is about a user switching to a more aggressive hair loss treatment, adding dutasteride 0.5mg and oral minoxidil 2.5mg to their current regimen of finasteride 0.02%, minoxidil 5%, biotin, massages, and microneedling. Users suggest increasing finasteride dosage and caution about potential side effects of oral minoxidil.

The user is experiencing reduced hair shedding and increased hair density after using finasteride, minoxidil, derma rolling, granactive retinoid, and Nizoral, while also taking testosterone and aromatase inhibitors. They question if they are a hyper responder to the treatments, despite mixed feedback from others about visible progress.

Hair loss has slowed or stopped after 5 months of daily oral minoxidil and finasteride treatment, with ketoconazole shampoo used twice a week. Noticeable thickening is observed, especially on the mid scalp.

The user has been using oral minoxidil and finasteride but has seen no regrowth, only stabilization of hair loss. Suggestions include considering a hair transplant or adding topical treatments, with some users sharing similar experiences of stabilization without regrowth.